Tonix Pharmaceuticals Files 8-K With Exhibits

Ticker: TNXP · Form: 8-K · Filed: Apr 24, 2025 · CIK: 1430306

Sentiment: neutral

Topics: financial-statements, exhibits, sec-filing

Related Tickers: TNXP

TL;DR

TNXP filed an 8-K with financial statements and exhibits, no major news.

AI Summary

On April 23, 2025, Tonix Pharmaceuticals Holding Corp. filed an 8-K report. The filing primarily consists of financial statements and exhibits, with no specific material events or regulatory disclosures detailed in the provided text. The company is incorporated in Nevada and its principal executive offices are located in Chatham, New Jersey.

Why It Matters

This 8-K filing indicates that Tonix Pharmaceuticals is providing updated financial statements and exhibits to the SEC, which is a standard procedural requirement for public companies.

Risk Assessment

Risk Level: low — The filing is a routine 8-K containing financial statements and exhibits, with no new material events or disclosures that would inherently increase risk.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report financial statements and exhibits as of April 23, 2025.

What is the exact name of the registrant?

The exact name of the registrant is Tonix Pharmaceuticals Holding Corp.

In which state is Tonix Pharmaceuticals Holding Corp. incorporated?

Tonix Pharmaceuticals Holding Corp. is incorporated in Nevada.

What is the address of the company's principal executive offices?

The address of the company's principal executive offices is 26 Main Street, Chatham, New Jersey, 07928.

What is the SEC file number for Tonix Pharmaceuticals Holding Corp.?

The SEC file number for Tonix Pharmaceuticals Holding Corp. is 001-36019.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on April 24, 2025 regarding Tonix Pharmaceuticals Holding Corp. (TNXP).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing